Design of efficient computational workflows for in silico drug repurposing

Drug Discovery Today

Volumn 22, Issue 2, 2017, Pages 210-222

  Vanhaelen, Quentin ^a   Mamoshina, Polina ^a   Aliper, Alexander M ^a   Artemov, Artem ^a   Lezhnina, Ksenia ^a   Ozerov, Ivan ^a   Labat, Ivan ^b   Zhavoronkov, Alex ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b BIOTIME INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FASUDIL; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE;

ALGORITHM; AUTOPHAGY; COMPUTER MODEL; DRUG IDENTIFICATION; DRUG REPOSITIONING; ENHANCER REGION; MACHINE LEARNING; PREDICTION; REVIEW; WORKFLOW; ANALOGS AND DERIVATIVES; COMPUTER SIMULATION; DRUG EFFECTS; HUMAN;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; AUTOPHAGY; COMPUTER SIMULATION; DRUG REPOSITIONING; HUMANS; WORKFLOW;

EID: 85000896742     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.09.019     Document Type: Review

References (101)

1. 1 Tollman, P., et al. Identifying R&D outliers. Nat. Rev. Drug Discov. 10 (2011), 653–654.
2. 2 Scannell, J.W., et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 1 (2012), 191–200.
3. 3 Ashburn, T.T., Thor, K.B., Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3 (2004), 673–683.
4. 4 Dudley, J.T., et al. Exploiting drug-disease relationships for computational drug repositioning. Brief. Bioinform. 12 (2011), 303–311.
5. 5 Munos, B.H., Chin, W.W., How to revive breakthrough innovation in the pharmaceutical industry. Sci. Transl. Med., 3, 2011, 89cm16.
6. 6 Mignani, S., et al. Why and how have drug discovery strategies in pharma changed? What are the new mindsets?. Drug Discov. Today 21 (2016), 239–249.
7. 7 Novac, N., Challenges and opportunities of drug repositioning. Trends Pharmacol. Sci. 34 (2013), 267–272.
8. 8 Mucke, H.A.M., Drug repurposing patent applications October–December 2015. Assay Drug Dev. Technol. 14 (2016), 308–312.
9. 9 Naylor, S., et al. Therapeutic drug repurposing, repositioning, and rescue: Part III. Market exclusivity using intellectual property and regulatory pathways. Drug Discov. World, 2015, 62–69.
10. 10 Mucke, H.A.M., Mucke, E., Sources and targets for drug repurposing: landscaping transitions in therapeutic space. Drug Repurpos. Rescue Reposition. 1 (2015), 22–27.
11. 11 Yarchoan, M., Arnold, S.E., Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 63 (2014), 2253–2261.
12. 12 Mucke, H.A.M., Drug repurposing for vascular dementia: overview and current developments. Future Neurol. 11 (2016), 215–225.
13. 13 Snell, W.T., et al. Repurposing FDA-approved drugs for anti-aging therapies. Biogerontology, 2016, 10.1007/s10522-016-9660-x Published online August 2, 2016.
14. 14 Shumei, K., et al. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience 2 (2015), 576–580.
15. 15 Rutika, R., et al. Tumor deconstruction as a tool for advanced drug screening and repositioning. Pharmacol. Res. 111 (2016), 815–819.
16. 16 Heckman-Stoddard, B.M., et al. Repurposing old drugs to chemoprevention: the case of metformin. Semin. Oncol. 43 (2016), 123–133.
17. 17 Gilbert, D.C., Repurposing Vitamin D as an anticancer drug. Clin. Oncol. 28 (2016), 36–41.
18. 18 Shim, J.S., Liu, J.O., Recent advances in drug repositioning for the discovery of new anticancer drugs. Int. J. Biol. Sci. 10 (2014), 654–663.
19. 19 Guney, E., et al. Network-based in silico drug efficacy screening. Nat. Commun., 7, 2016, 10331.
20. 20 Kaplan, W., et al. Priority Medicines for Europe and the World Update 2013. 2013, WHO.
21. 21 Hodos, R.A., et al. In silico methods for drug repurposing and pharmacology. WIREs Syst. Biol. Med. 8 (2016), 186–210.
22. 22 Wu, Z., et al. Network-based drug repositioning. Mol. BioSyst. 9 (2013), 1268–1281.
23. 23 Zou, J., et al. Advanced systems biology methods in drug discovery and translational biomedicine. BioMed Res. Int., 2013, 2013, 742835.
24. 24 Prathipati, P., Mizuguchi, K., Systems biology approaches to a rational drug discovery paradigm. Curr. Top. Med. Chem. 16 (2016), 1009–1025.
25. 25 Lavecchia, A., Cerchia, C., In silico methods to address polypharmacology: current status, applications and future perspectives. Drug Discov. Today 21 (2016), 288–298.
26. 26 Cichonska, A., et al. Identification of drug candidates and repurposing opportunities through compound–target interaction networks. Expert Opin. Drug Discov. 10 (2015), 1333–1345.
27. 27 Gonzalez-Daz, H., et al. Mind-best: web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae. J. Proteome Res. 10 (2011), 1698–1718.
28. 28 Xie, L., et al. Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput. Biol., 7, 2011, e1002037.
29. 29 Campillos, M., et al. Drug target identification using side-effect similarity. Science 321 (2008), 263–266.
30. 30 Pacini, C., et al. DvD: an R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data. Bioinformatics 29 (2013), 132–134.
31. 31 Jahchan, N.S., et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 3 (2013), 1364–1377.
32. 32 Putin, E., et al. Deep biomarkers of human aging: application of deep neural networks to biomarker development. Aging 8 (2016), 1021–1033.
33. 33 Aliper, A., et al. Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data. Mol. Pharm. 13 (2016), 2524–2530.
34. 34 Alaimo, S., et al. Recommendation techniques for drug–target interaction prediction and drug repositioning. Data mining techniques for the life sciences. Methods Mol. Biol. 1415 (2016), 441–462.
35. 35 Iorio, F., et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 14621–14626.
36. 36 Lamb, J., et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313 (2006), 1929–1935.
37. 37 Iorio, F., et al. Identifying network of drug mode of action by gene expression profiling. J. Comput. Biol. 16 (2009), 241–251.
38. 38 Diaconis, P., Graham, R., Spearman's footrule as a measure of disarray. J. R. Stat. Soc. 39 (1977), 262–268.
39. 39 Lin, S., et al. Space oriented rank-based data integration. Stat. Appl. Genet. Mol. Biol., 9, 2010, Article 20.
40. 40 Subramanian, A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 15545–15550.
41. 41 Newman, M.E., Modularity and community structure in networks. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 8577–8582.
42. 42 Frey, B.J., Dueck, D., Clustering by passing messages between data points. Science 315 (2007), 972–976.
43. 43 Gribskov, M., Robinson, N.L., Use of receiver operating characteristic (ROC) analysis to evaluate sequence matching. Comput. Chem. 20 (1996), 25–33.
44. 44 Ravikumar, B., et al. Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy. Hum. Mol. Genet. 12 (2003), 985–994.
45. 45 de Medina, P., et al. Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy 5 (2009), 1066–1067.
46. 46 Menche, J., et al. Uncovering disease–disease relationships through the incomplete interactome. Science, 347, 2015, 1257601.
47. 47 Chen, H., et al. Network-based inference methods for drug repositioning. Comput. Math. Methods Med., 2015, 2015, 130620.
48. 48 Gottlieb, A., et al. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol. Syst. Biol., 7, 2011, 496.
49. 49 Hu, G., Agarwal, P., Human disease–drug network based on genomic expression profiles. PLoS ONE, 4, 2009, e6536.
50. 50 Sirota, M., et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med., 3, 2011, 96ra77.
51. 51 Dai, W., et al. Matrix factorization-based prediction of novel drug indications by integrating genomic space. Comput. Math. Methods Med., 2015, 2015, 275045.
52. 52 Cheng, F., et al. Prediction of drug–target interactions and drug repositioning via network-based inference. PLoS Comput. Biol., 8, 2011, e1002503.
53. 53 Lee, H.S., et al. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug. BMC Syst. Biol., 6, 2012, 80.
54. 54 Huang, C.H., et al. Drug repositioning discovery for early- and late-stage non-small-cell lung cancer. BioMed Res. Int., 2014, 2014, 193817.
55. 55 Dudley, J.T., et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med., 3, 2011 96ra76.
56. 56 Jin, L., et al. Drug-repurposing identified the combination of Trolox C and Cytisine for the treatment of type 2 diabetes. J. Transl. Med., 12, 2014, 153.
57. 57 Kuhn, M., et al. Systematic identification of proteins that elicit drug side effects. Mol. Syst. Biol., 9, 2013, 663.
58. 58 Dorel, M., et al. Network-based approaches for drug response prediction and targeted therapy development in cancer. Biochem. Biophys. Res. Commun. 464 (2015), 386–391.
59. 59 Smith, S.B., et al. Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis. PLoS ONE, 7, 2012, e33174.
60. 60 Zeng, H., et al. Drug-Path: a database for drug-induced pathways. Database, 2015, 2015, bav061.
61. 61 Pan, Y., et al. Pathway analysis for drug repositioning based on public database mining. J. Chem. Inf. Model. 54 (2014), 407–418.
62. 62 Han, S., Kim, D., Inference of protein complex activities from chemical-genetic profile and its applications: predicting drug–target pathways. PLoS Comput. Biol., 4, 2008, e1000162.
63. 63 Yildirim, M.A., et al. Drug–target network. Nat. Biotechnol. 25 (2007), 1119–1126.
64. 64 Liu, H., et al. Improving compound–protein interaction prediction by building up highly credible negative samples. Bioinformatics 31 (2015), i221–i229.
65. 65 Sanseau, P., et al. Use of genome-wide association studies for drug repositioning. Nat. Biotechnol. 30 (2012), 317–320.
66. 66 Mullen, J., et al. An integrated data driven approach to drug repositioning using gene–disease associations. PLOS ONE, 11, 2016, e0155811.
67. 67 Cheung, W.A., et al. Compensating for literature annotation bias when predicting novel drug–disease relationships through Medical Subject Heading Over representation Profile (MeSHOP) similarity. BMC Med. Genomics, 6(Suppl. 2), 2013, S3.
68. 68 Chen, B., Butte, A.J., Leveraging big data to transform target selection and drug discovery. Clin. Pharmacol. Ther. 99 (2016), 285–297.
69. 69 Siragusa, L., et al. Comparing drug images and repurposing drugs with BioGPS and FLAPdock: the thymidylate synthase case. ChemMedChem 11 (2016), 1–15.
70. 70 Luo, H., et al. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res. 39 (2011), W492–W498.
71. 71 Keiser, M.J., et al. Predicting new molecular targets for known drugs. Nature 462 (2009), 175–181.
72. 72 Keiser, M.J., et al. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25 (2007), 197–206.
73. 73 Hert, J., et al. Quantifying the relationships among drug classes. J. Chem. Inf. Model. 48 (2008), 755–765.
74. 74 Zhou, T., et al. Solving the apparent diversity-accuracy dilemma of recommender systems. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 4511–4515.
75. 75 Alaimo, S., et al. Drug–target interaction prediction through domain-tuned network-based inference. Bioinformatics 29 (2013), 2004–2008.
76. 76 Nidhi, et al. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J. Chem. Inf. Model. 46 (2006), 1124–1133.
77. 77 Fernald, G.H., Altman, R.B., Using molecular features of xenobiotics to predict hepatic gene expression response. J. Chem. Inf. Model. 53 (2013), 2765–2773.
78. 78 Hansen, N.T., et al. Generating genome-scale candidate gene lists for pharmacogenomics. Clin. Pharmacol. Ther. 86 (2009), 183–189.
79. 79 Yamanishi, Y., et al. Prediction of drug–target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 24 (2008), i232–i240.
80. 80 Li, J., Lu, Z., Pathway-based drug repositioning using causal inference. BMC Bioinform., 14(Suppl. 16), 2013, S3.
81. 81 Yang, L., Agarwal, P., Systematic drug repositioning based on clinical side-effects. PLoS ONE, 6, 2011, e28025.
82. 82 Rendle, S., Factorization machines with libFM. ACM Trans. Intell. Syst. Technol. 3 (2012), 1–22.
83. 83 Chen, T., et al. SVDFeature: a toolkit for feature-based collaborative filtering. J. Mach. Learn. Res. 13 (2012), 3619–3622.
84. 84 Mei, J.P., et al. Drug–target interaction prediction by learning from local information and neighbors. Bioinformatics 29 (2013), 238–245.
85. 85 Schlkopf, B., et al. (eds.) Kernel Methods in Computational Biology, 2004, MIT Press.
86. 86 Bleakley, K., Yamanishi, Y., Supervised prediction of drug–target interactions using bipartite local models. Bioinformatics 25 (2009), 2397–2403.
87. 87 van Laarhoven, T., et al. Gaussian interaction profile kernels for predicting drug–target interaction. Bioinformatics 27 (2011), 3036–3043.
88. 88 Raghavan, V.V., et al. A critical investigation of recall and precision as measures of retrieval system performance. ACM Trans. Inf. Syst. 7 (1989), 205–229.
89. 89 Zhao, S., Li, S., A co-module approach for elucidating drug-disease associations and revealing their molecular basis. Bioinformatics 28 (2012), 955–961.
90. 90 Daminelli, S., et al. Drug repositioning through incomplete bi-cliques in an integrated drug–target–disease network. Integr. Biol. 4 (2012), 778–788.
91. 91 Wang, K., et al. Opportunities for web-based drug repositioning: searching for potential antihypertensive agents with hypotension adverse events. J. Med. Internet Res., 18, 2016, e76.
92. 92 Oquab, M., et al. Learning and transferring mid-level image representations using convolutional neural networks. Proc. 2014 IEEE Conf. Computer Vision Pattern Recogni., 2014, 1717–1724.
93. 93 Ma, J., et al. Deep neural nets as a method for quantitative structure-activity relationships. J. Chem. Inf. Model. 55 (2015), 263–274.
94. 94 Wang, C., et al. Pairwise input neural network for target–ligand interaction prediction. 2014 IEEE Int. Conf. Bioinformatics Biomed., 2014, 67–70.
95. 95 Mamoshina, P., et al. Applications of deep learning in biomedicine. Mol. Pharm. 13 (2016), 1445–1454.
96. 96 Xu, Y., et al. Deep learning for drug-induced liver injury. J. Chem. Inf. Model. 55 (2015), 2085–2093.
97. 97 Hughes, T.B., et al. Modeling epoxidation of drug-like molecules with a deep machine learning network. ACS Cent. Sci. 1 (2015), 168–180.
98. 98 Mayr, A., et al. DeepTox: toxicity prediction using deep learning. Front. Environ. Sci., 2016 Published online February 2, 2016 http://dx.doi.org/10.3389/fenvs.2015.00080.
99. 99 Ramsundar, B., et al. Massively Multitask Networks for Drug Discovery. 2015 arXiv:1502.02072.
100. 100 Dahl, G.E., et al. Multi-task Neural Networks for QSAR Predictions. 2014 arXiv:1406.1231.
101. 101 Karim, A., Zhou, S., X-TREPAN: A Multi-class Regression and Adapted Extraction of Comprehensible Decision Tree in Artificial Neural Networks. 2015 arXiv:1508.07551.